Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Almirall and Proteros Biostructures have achieved a scientific milestone in their collaboration -in force since mid 2006- to solve structures of a prominent Almirall drug discovery target in combination with proprietary Almirall compounds triggering commercial payments to Proteros.
Subscribe to our email newsletter
Proteros applied its industrial structural biology platform and proprietary technologies to deliver protein ligand structures to Almirall Scientists for a known, extremely challenging protein where little published data is available, particularly on solving specific protein ligand structures.
Proteros delivered the solved structures within the timeframes agreed at the beginning of the collaboration.
Torsten Neuefeind, CEO of proteros, said: “we are pleased that Proteros’s approach to structural biology, of applying our unique technologies in an industrial process, has proven to offer an effective and valuable service to our client’s scientists allowing them to make early decision on their drug discovery programs.”